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136 BEDARD ET ALBackground: Mobile health can be used to generate innovative
insights into optimizing treatment to improve allergic rhinitis
(AR) control.
Objectives: A cross-sectional real-world observational study
was undertaken in 22 countries to complement a pilot study and
provide novel information on medication use, disease control,
and work productivity in the everyday life of patients with AR.
Methods: A mobile phone app (Allergy Diary, which is freely
available on Google Play and Apple stores) was used to collect the
data of daily visual analogue scale (VAS) scores for (1) overall
allergic symptoms; (2) nasal, ocular, and asthma symptoms; (3)
work; and (4) medication use by using a treatment scroll list
including all allergy medications (prescribed and over-the-
counter) customized for 22 countries. The 4 most common
intranasal medications containing intranasal corticosteroids and
8 oral H1-antihistamines were studied.
Results: Nine thousand one hundred twenty-two users filled in
112,054 days of VASs in 2016 and 2017. Assessment of days wasPopulation Health Sciences and Informatics, University of Edinburgh; vvSkin and Al-
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control), single (good control for intranasal corticosteroid–treated
days), or multiple (worst control) treatments. Users with the worst
control increased the range of treatments being used. The same
trend was found for asthma, eye symptoms, and work productivity.
Differences between oral H1-antihistamines were found.
Conclusions: This study confirms the usefulness of the Allergy
Diary in accessing and assessing behavior in patients with AR. This
observational study using a very simple assessment tool (VAS) on a
mobile phone had the potential to answer questions previously
thought infeasible. (J Allergy Clin Immunol 2019;144:135-43.)
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on randomized controlled trials (RCTs), which are typically
undertaken in highly selected populations, often with limited/
unclear generalizability to routine care contexts.1,2 They propose
to increase treatment to achieve disease control (ie, sleep, social,
and school/work impairment), which is the ultimate aim of the
treatment. Intranasal corticosteroids (INCSs) represent the most
effective AR treatment for most patients, but their effect is rela-
tively slow, taking several hours,3 and many patients prefer oral
medications. A formulation of fluticasone propionate (FP) and
azelastine (AzeFlu) is more effective than INCSs alone4 and
has the advantage of acting within minutes.5
Patients are poorly adherent to treatment and often self-
medicate.6,7 They want more effective and fast-acting treatments.
Therefore observational real-life studies are needed to comple-
ment RCTs to better understand the efficacy of INCS-
containing medications because RCTs do not select patients
and report their behavior.
Mobile Airways Sentinel Network (MASK) for allergic
rhinitis, an information and communications technology system
centered around the patient8-12 that is operational in 23 countries,
uses a treatment scroll list including all medications customized
for each country and a visual analogue scale (VAS) to assess
rhinitis control. A pilot study in more than 2,900 users allowed
differentiation between treatments.13 Patients did not necessarily
use treatment on a daily basis in a regular way but appeared to in-
crease treatment usewhen their symptom control worsened. How-
ever, the pilot study needs to be confirmedwith a larger number of
users and more medications tested.
The present cross-sectional observational study was under-
taken in 9,122 users in 22 countries (data collection had only
just started in Argentina) to confirm the pilot study13 using the
same methods and to bring novel information on medication
use and associated disease control, work productivity,14 and
allergic multimorbidity.13 The study was focused first on the
4 most commonly used intranasal medications containing
INCSs: fluticasone furoate (FF), FP, mometasone furoate
(MF), and AzeFlu. We did not perform the same analysis
with oral H1-antihistamines (OAHs) because they are often
associated with INCSs, and many patients would have been
analyzed twice. In the second analysis, we examined some
widely used OAHs: bilastine, cetirizine, desloratadine, ebas-
tine, fexofenadine, levocetirizine, loratadine, and rupatadine.
In the first analysis, we compared days with single treatment
with days with multiple treatments. In the second analysis,
we just used days with a single treatment.METHODS
Users
All consecutive users from January 1, 2016, to December 31, 2017 were
included with no exclusion criteria according to methods previously
described.13,14
Setting
Users from 22 countries filled in theAllergyDiary (Table I). Data collection
had only just started in Argentina, and results are not included.
Ethics
TheAllergy Diary is CE1. CEmarking is a certification that indicates confor-
mity with health, safety, and environmental protection standards for products
made in the EuropeanUnion andmeets the essential requirements of all relevant
European Medical Device Directives.15 CE1 includes sterile and nonsterile
products and assesses whether the device has a measuring function.
Data were anonymized, including data related to geolocalization, by using
k-anonymity.16 Independent review board approval was not required because
the study was observational, and users had agreed to having their data
analyzed (terms of use).
Allergy Diary
Geolocalized users assess their daily symptom control by using the
touchscreen functionality on their smart phone to click on 5 consecutive VAS
scores (ie, general, nasal symptoms, ocular symptoms, asthma, andwork). Users
input their daily medications using a scroll list that contains all country-specific
over-the-counter medications and prescribed medications available for each
country (see Fig E1 in this article’s Online Repository at www.jacionline.org).
The list has been populated with Information Management System data. Days
reported by users included days with or without treatment.
The present study is anotherAllergy Diary study. Some of the raw data used
in the first article (up to November 2016)13 were used in this study, but ana-
lyses differed.
Medication selection
The International Nonproprietary Names classification was used for drug
nomenclature.17 Monotherapy was defined as days when only a single medi-
cation for rhinitis was reported. AzeFlu contains 2 drugs, but because it is a
fixed combination, it was considered a monotherapy. Comedication was
defined as days with 2 or more medications for rhinitis. Asthma medications
were not considered in comedication.
Study size
In this study, all registered users were included to obtain the best possible
estimates for the specified time window. From the pilot study, numbers tested
largely exceed those needed to find significant differences in the full-set
analysis.13 However, we did not consider medications with a sample size of
less than 1,000 days of reporting.
Statistical methods
A non-Gaussian distribution was found for the data. Nonparametric tests
and medians (and percentiles) were used. Correction for multiple testing was
made, when appropriate.
Some users reportedVAS scoresmore than once a day. In the pilot study, we
found that the highest reported value should be used, and we followed this
study.13 However, in an exploratory analysis, we tested VAS scores in dupli-
cates and multiplicates.
Data analysis
As previously published,13 we conducted separate analyses by using the
full set of data and data on just the first day of reporting. In the first analysis,
TABLE I. Country and number of users recording VAS scores by using the Allergy Diary in the full data set
Country
VAS measurements (d)
Total1 2-7 8-14 >14
Austria 226 (56.6%) 121 16 36 399
Australia 49 (49.0%) 30 10 11 100
Belgium 48 (49.5%) 35 5 9 97
Brazil 572 (55.9%) 323 67 62 1024
Canada 6 (35.3%) 7 3 1 17
Czech Republic 1 (20.0%) 0 1 3 5
Denmark 37 (45.1%) 29 4 12 82
Finland 117 (44.8%) 93 25 26 261
France 319 (61.3%) 147 19 35 520
Germany 208 (39.8%) 141 35 139 523
Greece 47 (23.7%) 43 24 84 198
Italy 554 (44.6%) 389 87 213 1243
Lithuania 59 (17.7%) 89 52 134 334
Mexico 101 (13.0%) 207 128 343 779
The Netherlands 167 (53.9%) 94 23 26 310
Poland 286 (54.9%) 159 28 48 521
Portugal 647 (49.2%) 505 64 100 1316
Spain 129 (30.5%) 124 53 117 423
Sweden 33 (39.3%) 34 6 11 84
Switzerland 247 (64.0%) 111 11 17 386
Turkey 81 (52.6%) 42 10 21 154
United Kingdom 148 (42.8%) 104 46 48 346
Total 4082 (44.7%) 2827 (31.0%) 717 (7.9%) 1496 (16.4%) 9122
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and AzeFlu were studied (see Fig E2 in this article’s Online Repository at
www.jacionline.org). Those receiving other INCSs were excluded. For come-
dication, we initially selected second-generation OAHs: cetirizine, deslorata-
dine, ebastine, fexofenadine, levocetirizine, loratadine, and rupatadine
(group 1 OAH). There are many other OAHs, but we did not consider them
because their pharmacologic properties vary widely, and they were not used
often. We considered 2 other groups in INCS users for comedication: users
who reported an OAH and another medication (groupOAH1 other) and users
who reported another medication (1 other). Users who reported other medi-
cations but no INCSs were not analyzed. As a primary end point, using the
full data set, we studied median VAS global scores (‘‘Overall, how much
are your allergic symptoms bothering you today?’’) levels for days with FF,
FP, MF, and AzeFlu and for days without medications. The primary and sec-
ondary end points were analyzed by using the Kruskal-Wallis test and Wil-
coxon and Mann-Whitney tests with Dunn-Bonferroni post hoc analysis to
correct for multiple testing. Moreover, we analyzed the data using 3 cutoffs,
according to a consensus18 and available data of the pilot study13,14: controlled
days, VAS score of less than 20 of 100; days with moderate control, VAS score
of 20 to 49; and days with poor control, VAS score of 50 or greater. The same
analyses were conducted for the first day of VAS report. Secondary end points
included VAS eye, asthma, and work.
In the second analysis, we compared days with monotherapy for the most
common OAH: cetirizine, desloratadine, ebastine, fexofenadine, levocetir-
izine, loratadine, and rupatadine monotherapy. We did not consider other
OAHs with a sample size of less than 1,000 days (or close to this number). We
only compared VAS global scores measured. The mean number of days of
reporting was considered for each treatment.
We then performed exploratory analyses to investigate whether there are
temporal patterns in the reporting of VAS among app users. We assessed VAS
scores on (1) days with more than 1 VAS reported, (2) the first day of reporting
and first day of new reporting in users with nonconsecutive data, (3) days
without treatment followed by a day with treatment, and (4) days with
treatment followed by a day without treatment.RESULTS
Demographic characteristics
The study included 9,122 users. Roughly 5% of users did not
report their age and were ascribed to 0. Users ranged in age from
0 to 92 years (mean6 SD, 32.46 15.2 years). There were 54.7%
women and 45.3% men. The age repartition is shown in Fig E3 in
this article’s Online Repository at www.jacionline.org.
A total of 112,054 days were recorded. Duplicates or multi-
plicates for the same day were found for 14,767 days. Global VAS
scores were not recorded in 754 (0.8%) days with app data
reported. There were 52,706 (54.6%) days without treatment and
18,117 days with the targeted INCS (Fig 1).Analysis of VAS global scores measured
Onvisual inspection, no clear trajectory of VAS scores could be
easily identified because users erratically reported their VAS and
treatment data. Fig E4 in this article’s Online Repository at www.
jacionline.org reports trajectories for French users as an example.
In the figure, each user is identified by amember identifier number
(vertical axis), and each user’s trajectory is represented horizon-
tally by dots, with each dot representing a day of VAS recording.
Results are reported in Figs 2 and 3 and Table II.Analysis of VAS global scores measured on days
without treatment and days with INCS treatment
On the first day of reporting, VAS scores were reported by
4,991 users without treatment, 1,395 users with OAH treatment,
and 1,281 users with INCS treatment (Table II). The percentage of
users with a single treatment ranged from 34.0% (FP) to 39.2%
FIG 2. Percentage of days in each category of INCS treatment (first day and
full data set).
FIG 1. Flowchart of the study population.
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had similar median VAS scores (35-44).
For the full data set of 96,533 days, VAS scores were reported
by 6,236 users without treatment, 3,664 users with OAH
treatment, and 2,575 users with INCS treatment (Table II). Mono-
therapy was reported on 45% to 55% of these days (FF or MF vs
AzeFlu, Fig 2). For monotherapy, median VAS scores ranged
from 5 (FF) to 23.5 (FP). For day 1 and the full data set, the
same trendwas found in INCS-treated users: lowest median levels
were found for monotherapy, increased levels for comedication
with OAHs, and highest levels for comedication with OAHs
plus other treatments (Fig 3). Variable VAS scores were observed
for comedication with other treatments. The numbers of days of
comedication with another INCS were too low to make any com-
parison (Table II).Analysis of VAS global scores measured on days
with OAH treatment alone
The first day of reporting, days with no treatment and days with
INCS monotherapy had similar median VAS scores (range, 34-
44). On the other hand, there were some variations for OAHs in
monotherapy. Levocetirizine days had a median VAS score of
intermediate between untreated or INCS-treated days and the
other OAHs. For the full data set of 96,533 days, median VAS
scores of days with INCSs were lower than those of days with
OAHs, but bilastine, fexofenadine, levocetirizine, and rupatadine
had scores similar to those of INCSs (Table II).
Apart from days with FP treatment (low numbers), the mean
numbers of days of reporting medications per user ranged from
4.00 (cetirizine) to 8.98 (AzeFlu).Analyses of VAS scores for eye symptoms, asthma,
and work productivity
Analyses of VAS scores for eye symptoms, asthma, and work
productivity are reported in Fig E5 in this article’s Online Repos-
itory at www.jacionline.org. Trends for the 3 secondary end points
are similar to those of VAS global scores measured (ie, low me-
dian scores similar to those of untreated days for the single treat-
ment, increased scores with comedication with an OAH, and
highest scores for comedication with an OAH plus another medi-
cation and the highest percentage of users with single treatment
observed for AzeFlu). Fewer users reported VAS work, but the
trends were similar.Exploratory analyses investigating potential
temporal patterns in the reporting of VAS scores
Assessment of duplicates or multiplicates for day 1.
Days with 2 or more VAS scores reported at least 1 hour apart
within the same day were selected. The data set included
1,576 days for VAS global scores measured. A significantly
higher VAS score was found at the second reporting compared
with the first. When data were stratified by the type of treatment
recorded at first entry (no treatment, AzeFlu FF, MF, and FP),
these findingswere only significant for dayswith no treatment. No
difference was found for days with (any) treatment (see Table E1
in this article’s Online Repository at www.jacionline.org).
VAS scores depending on consecutive and noncon-
secutive data. There were 4,132 users with at least 2
nonconsecutive calendar days of VAS scores reported
(n 5 89,473 days in total). Global VAS scores measured on day
1 were found to be significantly greater when compared with
global VAS scores measured on the first day of new reporting (ie,
on first nonconsecutive calendar day reported), regardless of the
presence/type of treatment (Table III).
Distribution of global VAS scores on the 391 consecutive
couple of calendar days consisting of a day without treatment
followed by a day with treatment showed a nonsignificant
increased score in treated days (median, 23 [25th-75th percentile
{p25-75}, 11-49] to 28 [p25-75, 14-50]; P 5 .07, Wilcoxon W
test).
Distribution of global VAS scores on the 350 consecutive
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FIG 3. Percentage of days in each category of treatment for VAS global measured (full data set).
TABLE II. Results of VAS global scores measured
Day 1 Full set (96,533 d)
Mean no of days per userNo. of days Median (p25-p75) No. of days (users) Median (p25-p75)
No treatment 4,991 34 (10-60) 52,706 (6,236) 8 (0-26) 8.45
Bilastine* 128 48 (19-69.5) 1,563 (261) 16 (6-37) 6.00
Cetirizine* 350 52 (28-70) 2,169 (545) 22 (9-50) 4.00
Desloratadine* 300 50 (26-71) 2,085 (504) 21 (8-46) 4.14
Ebastine* 115 50 (26-72) 980 (201) 23 (9-48) 4.88
Fexofenadine* 112 55 (32.5-71.5) 1,128 (183) 14 (8-35) 6.17
Levocetirizine* 149 43 (16-67) 1,512 (260) 14 (5-28) 5.81
Loratadine* 175 49 (28-72) 1,680 (344) 21 (10-39) 4.88
Rupatadine* 66 49 (23-63) 1,138 (146) 18 (5-36) 7.69
FF 176 35 (19.5-58.5) 2,182 (336) 5 (0-27) 6.49
1 OAH 129 51 (22-66) 1,317 (247) 21 (4-45) 5.33
1 OAH 1 other 38 64 (49-77) 307 (80) 48 (24-63) 3.84
1 other (no OAH) 84 53.5 (28-72) 968 (168) 23 (9-47) 5.76
1 other INCS 7 50 (4-90) 113 (16) 61 (26-95) 7.06
AzeFlu 155 37 (16-60) 2,722 (303) 13 (3-29) 8.98
1 OAH 49 58 (40-73) 994 (113) 17 (7-40) 8.72
1 OAH 1 other 12 54 (26-80) 174 (33) 31 (9-60) 5.27
1 other (no OAH) 37 40 (21-65) 871 (98) 22 (11-42) 8.89
1 other INCS 7 50 (33-77) 193 (21) 36 (12-73) 8.39
MF 192 36.5 (16.5-59.5) 3,420 (409) 15 (5-28) 7.92
1 OAH 144 48 (23-68) 2,181 (284) 17 (8-37) 7.68
1 OAH 1 other 64 61.5 (33.5-75) 914 (114) 26 (14-49) 8.02
1 other (no OAH) 83 53 (26-68) 1,158 (167) 26 (9-45) 6.93
1 other INCS 7 33 (0-77) 113 (21) 20 (6-79) 5.38
FP 33 44 (30-65) 156 (55) 23.5 (3.5-52) 2.83
1 OAH 34 56 (40-67) 305 (64) 19 (10-46) 4.77
1 OAH 1 other 14 52.5 (45-80) 60 (21) 54 (24.5-82.5) 2.89
1 other (no OAH) 13 41 (31-59) 121 (22) 22 (18-41) 5.50
1 other INCS 3 4 (0-65) 127 (11) 22 (8-48) 11.55
*Monotherapy.
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TABLE III. Day 1 versus nonconsecutive days








Day 1 vs first
nonconsecutive day
All days 4,132 34 (12-60) 4,132 25 (7-51) 24,680 12 (2-32) <.001
No treatment 2,214 26 (7-51) 2,154 18 (4-44) 13,651 8 (0-24) <.001
AzeFlu 162 44 (19-69) 187 26 (9-55) 1,566 17 (6-35) <.001
Other INCS treatment 555 43 (22-64) 601 30 (11-55) 3,403 17 (6-38) <.001
*Statistical analysis by using Wilcoxon and Mann-Whitney tests.
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decreased score in untreated days (median, 23 [p25-75, 13-45] to
20 [p25-75, 9-38]; P 5 .01 Wilcoxon W test).DISCUSSION
A pilot study using a very simple assessment (VAS) on a cell
phone in 2,871 users who filled in 17,091 days of data suggested
that an app might provide novel information concerning the
treatment of AR.13 However, the sample size was possibly too
small to draw definite conclusions. This study in a larger sample
(9,111 users in 22 countries, 97,287 days) confirms the findings of
the pilot study, showing that in real life the assessment of days can
inform a patient’s treatment and bring novel insight into the
behavior of patients with AR toward treatment and novel concepts
for change management of AR.19 The control of days differs be-
tween no treatment (best control), single treatment, or comedica-
tion (worst control). For the first time, this study showed that the
same trends were observed for global symptoms, ocular symp-
toms, asthma, andwork productivity. This study suggests contrary
behavior between physicians and patients because the range of
treatments was increased in those with poor control, whereas, ac-
cording to guidelines, physicians are recommended to increase
the treatment to achieve control. This major gap in AR treatment
might explain the overall low level of satisfaction of patients with
severe AR reported in many studies.Strengths and limitations
The current study has many strengths, including larger
numbers, multiple countries, range of treatments studied, and
patient/person-generated data.
As for all studies using participatory data, potential biases
include (1) the likelihood of a sampling bias being present and the
difficulty of assessing the generalizability of the study and (2)
outcome misclassification that cannot be assessed and, by
definition because of ethical problems, very little information
on patient (or day) characteristics. App users are not representa-
tive of all patients with rhinitis. The issue of potential selection
bias was limited by the fact that we considered days and not
patients in the analyses.
As in other studies,13,20 we used days in a cross-sectional anal-
ysis because there is no clear pattern of treatment, and a longitu-
dinal study was not feasible because users mostly use the app
intermittently. Although this observation might differ from
RCTs, our study is a real-life approach.
For this study, other biases should be considered. The diagnosis
of AR was not supported by a physician but was a response to the
following question: ‘‘Do you have allergic rhinitis? Yes/No.’’
Therefore there could be some users without AR who might haveresponded ‘‘yes’’ to the question. There are potential measure-
ment biases when using apps, including collection of information,
education of the patient, availability, and ability to use a
smartphone.13 Users self-identified themselves as having AR
without confirmation of the diagnosis. Precise patient character-
ization is impossible by using an app, but every observational
study using the Allergy Diary was able to identify days with
poor control or criteria of severity.20-24 Adherence to treatment
is impossible to prove because users do not report data on all
days and might not report all medications used. Nonetheless, mo-
bile technology is becoming an important tool for better under-
standing and managing AR and for providing novel information
that was not available with other methods.20-26
Asthmawas assessed by using a single VAS largely validated in
patients with rhinitis.27 In asthmatic patients, VAS scores were
shown to be an effective measure of control.28 In the present
study, we did not investigate specific symptoms or perform any
pulmonary function tests. Thus it is possible that some users
might have misunderstood the question or overestimated the dis-
ease. However, the results are extremely consistent.
We only considered days and not patients’ trajectories because
these are highly variable, with patients using automedication
depending on AR control, as previously shown.13
Longitudinal capture is very challenging with this app, but this
appears to be the case for all apps. Patient engagement with digital
health in real-world scenarios is usually lower than in RCTs.
Although this is a limitation in relation to causal inference, it
suggests that a newmethodological approach is needed. It appears
that treatment trajectories are specific for almost each user, and
most users have gaps in their treatment when their symptoms are
well controlled.Interpretation of the results and generalizability
This real-world assessment of the Allergy Diary using the VAS
allows assessment of treatment efficacy by days, which represents
real-life estimation of AR control. It also most likely reflects real
life better than patients’ assessments at regular intervals because
(1) it is known that AR is a highly variable disease and control
varies widely between days in relation to allergen and environ-
mental exposure, (2) patients are rarely adherent to their treat-
ment, (3) patients often stop treatment when they feel better,
and (4) patients increase their treatment when symptoms are
uncontrolled.
VAS scores were greater on days with treatment than on days
without treatment. This study confirms the results of the pilot
study,13 in which median VAS scores on days without treatment
were similar in users who never reported any medication
use and in those who were occasionally treated. Moreover, in a
small sample it was found that consecutive days with treatment
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treated users, days with a single treatment were better controlled
than days with multiple treatments. An important message from
this article is that overall in real life patients treat themselves
when they have symptoms and stop their treatment when their
symptoms are controlled. This is in agreement with previous
data.29,30 Using objective data, this study confirmed that adher-
ence is poor. Most patients with AR can have mild and/or inter-
mittent disease that does not require regular treatment to
achieve control. The concept of proactive medication and patient
participation,31 with the patient starting treatment when experi-
encing symptoms and continuing for a few days after getting con-
trol, might be of great interest and could be tested with the app. In
asthmatic patients, self-guided treatment was found to be of inter-
est.31-33 Such real-life findings might ultimately affect the way in
which guidelines are constructed to align them more with human
behavior. We have already initiated a program entitled change
management in patients with rhinitis and asthma19 in which we
propose to develop next-generation care pathways and test the
recommendations of GRADE guidelines in AR3,4 according to
real-world evidence using MASK data. A first meeting was
held at the Pasteur Institute, Paris, France (December 3, 2018),
to provide guidance for their development.
This observational studymade it possible to differentiate OAHs
and INCSs, confirming known data,34 and was able to differen-
tiate between OAHs. Levocetirizine was found to be the most
effective OAH, confirming clinical experience. On the other
hand, cetirizine appeared not to have been as effective. However,
therewere a large number of generics for cetirizine, and this could
be studied when more users are available. This study could also
differentiate the 3 medications containing INCSs, FF, MF, and
MP-AzeFlu, and confirm previous studies,35,36 extending our un-
derstanding of how AR treatment is used. RCTs showed that MP-
AzeFlu is more effective than single components available in
pharmacies37 or components using the same formulation.38
The same trends for INCS-containing medications were
observed for VAS global scores measured, eye symptoms,
asthma, and work productivity. However, the percentages of
well-controlled, controlled, and poorly controlled days differed,
indicating the independence of data already observed. Moreover,
data on work are extremely important for facilitating an economic
evaluation of treatments.
An important result is that VAS scores on day 1 were higher
than those on any other consecutive/nonconsecutive day. This
indicates that patients start using the app when symptoms are
uncontrolled. This is one specificity of analyzing app data and
should be considered in studies that assess control of allergic
diseases in relation to risk factors, such as air pollutants and
allergen exposure.CONCLUSIONS
Real-world data and real-world evidence play an increasing
role in health care decisions, supporting clinical trial designs and
observational studies to generate innovative and new treatment
approaches. These data hold potential to answer questions
previously thought infeasible,39 such as the true patient’s attitude
toward treatment. This observational study shows highly consis-
tent results between different outcomes (VAS scores) and pro-
vides novel concepts for the management of allergic diseases.
When the patient experiences increased symptoms, indicating aloss of control, he or she increases the number of medications
used that day. A total behavioral disconnectionwas found because
most patients treat themselves on demand when they are not
controlled, whereas the vast majority of physicians prescribe
long-term treatment to achieve control. Shared decision making
might offer a more rewarding approach to AR management.
The results of this article will be of importance for the implemen-
tation of the MASK Good Practices recently recognized by D. G.
Sante.
Clinical implications: A behavioral disconnect was found in the
study because patients are not adherent to treatment and treat
themselves on demand when their symptoms are not controlled,
whereas the vast majority of physicians prescribe long-term
treatment to achieve control. Shared decision making is
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FIG E1. Allergy Diary.
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FIG E2. Groups of users studied and excluded in the first analysis.
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FIG E3. Age distribution.
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FIG E4. VAS scores reporting trajectories in French users (n 5 520 users,
3,114 days).
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FIG E5. Percentage of days in each category of treatment for VAS scores for eye symptoms (A), asthma (B),
and work productivity (C; full data set).
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TABLE E1. Variations in VAS global scores within the same day
Days with >1 VAS score No. of days
VAS global score, median (p25-p75) P value*
First entry Second entry First vs second entry
All days 1576 18 (4-45) 22 (6-50) .01
Days without treatment 866 14 (0-36) 17 (3-42) .005
Days with AzeFlu treatment 140 13 (4-41.5) 14 (4.5-53) .58
Days with other INCS treatment 177 29 (8-51) 25 (9-54) .90
*Statistical analysis was performed with Wilcoxon and Mann-Whitney tests.
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